ReviewJMIR mHealth and uHealth2023
Personal Information Protection and Privacy Policy Compliance of Health Code Apps in China: Scale Development and Content Analysis.
Review in JMIR mHealth and uHealth, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Data-Driven Healthy China Pathway: Evolution, Framework, and Global Implications of National Digital Health Strategic Planning.Journal of medical Internet research · 2026Article
- Privacy Policy Compliance of Mobile Sports and Health Apps in China: Scale Development, Data Analysis, and Prospects for Regulatory Reform.JMIR mHealth and uHealth · 2026Article
- Personal medical data protection of mobile pharmacy apps in China 2025: scale development and content analysis.Archives of public health = Archives belges de sante publique · 2026Article
- Quality and Privacy Policy Compliance of Mental Health Care Apps in China: Cross-Sectional Evaluation Study.Journal of medical Internet research · 2025Article
- Medical Information Protection in Internet Hospital Apps in China: Scale Development and Content Analysis.JMIR mHealth and uHealth · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Digital technologies, especially contact tracing apps, have been crucial in monitoring and tracing the transmission of COVID-19 worldwide. China developed health code apps as an emergency response to the pandemic with plans to use them for broader public health services. However, potential problems within privacy policies may compromise personal information (PI) protection. Objective: We aimed to evaluate the compliance of the privacy policies of 30 health code apps in the mainland of China with the Personal Information Protection Law (PIPL) and related specifications. Methods: We reviewed and assessed the privacy policies of 30 health code apps between August 26 and September 6, 2023. We used a 3-level indicator scale based on the information life cycle as provided in the PIPL and related specifications. The scale comprised 7 level-1 indicators, 26 level-2 indicators, and 71 level-3 indicators. Results: The mean compliance score of the 30 health code apps was 59.9% (SD 22.6%). A total of 13 (43.3%) apps scored below this average, and 6 apps scored below 40%. Level-1 indicator scores included the following: general attributes (mean 85.6%, SD 23.3%); PI collection and use (mean 66.2%, SD 22.7%); PI storage and protection (mean 63.3%, SD 30.8%); PI sharing, transfer, disclosure, and transmission (mean 57.2%, SD 27.3%); PI deletion (mean 52.2%, SD 29.4%); individual rights (mean 59.3%, SD 25.7%); and PI processor duties (mean 43.7%, SD 23.8%). Sensitive PI protection compliance (mean 51.4%, SD 26.0%) lagged behind general PI protection (mean 83.3%, SD 24.3%), with only 1 app requiring separate consent for sensitive PI processing. Additionally, 46.7% (n=14) of the apps needed separate consent for subcontracting activities, while fewer disclosed PI recipient information (n=13, 43.3%), safety precautions (n=11, 36.7%), and rules of PI transfer during specific events (n=10, 33.3%). Most privacy policies specified the PI retention period (n=23, 76.7%) and postperiod deletion or anonymization (n=22, 73.3%), but only 6.7% (n=2) were committed to prompt third-party PI deletion. Most apps delineated various individual rights: the right to inquire (n=25, 83.3%), correct (n=24, 80%), and delete PI (n=24, 80%); cancel their account (n=21, 70%); withdraw consent (n=20, 60%); and request privacy policy explanations (n=24, 80%). Only a fraction addressed the rights to obtain copies (n=4, 13.3%) or refuse advertisement of automated decision-making (n=1, 3.3%). The mean compliance rate of PI processor duties was only 43.7% (SD 23.8%), with significant deficiencies in impact assessments (mean 5.0%, SD 19.8%), PI protection officer appointment (mean 6.7%, SD 24.9%), regular compliance audits (mean 6.7%, SD 24.9%), and complaint management (mean 37.8%, SD 39.2%). Conclusions: Our analysis revealed both strengths and significant shortcomings in the compliance of privacy policies of health code apps with the PIPL and related specifications considering the information life cycle. As China contemplates the future extended use of health code apps, it should articulate the legitimacy of the apps' normalization and ensure that users provide informed consent. Meanwhile, China should raise the compliance level of relevant privacy policies and fortify its enforcement mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.